Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase

被引：0
|
作者：
Henry, SP
Monteith, D
Bennett, F
Levin, AA
机构：
来源：
ANTI-CANCER DRUG DESIGN | 1997年 / 12卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：409 / 420
页数：12
相关论文
共 12 条
  • [1] First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase
    Monia, BP
    OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS, 1997, 209 : 107 - 119
  • [2] First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase - Discussion
    Inouye
    Monia
    Eckstein
    Gewirtz
    Toulme
    Helene
    Lebleu
    Agrawal
    Akhtar
    Southern
    Iversen
    Crooke
    Wickstrom
    Gait
    OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS, 1997, 209 : 119 - 123
  • [3] Synthesis of an antisense oligonucleotide targeted against C-raf kinase: Efficient oligonucleotide synthesis without chlorinated solvents
    Krotz, AH
    Cole, DL
    Ravikumar, VT
    BIOORGANIC & MEDICINAL CHEMISTRY, 1999, 7 (03) : 435 - 439
  • [4] Cholesterol conjugated uniform and gapmer phosphorothioate oligonucleotides targeted against PKC-alpha and C-raf gene expression
    Manoharan, M
    Tivel, KL
    Inamati, G
    Monia, BP
    Dean, N
    Cook, PD
    NUCLEOSIDES & NUCLEOTIDES, 1997, 16 (7-9): : 1139 - 1140
  • [5] Second generation antisense oligonucleotides-inhibition of PKC-alpha and c-RAF kinase expression by chimeric oligonucleotides incorporating 6'-substituted carbocyclic nucleosides and 2'-O-ethylene glycol substituted ribonucleosides
    Altmann, KH
    Martin, P
    Dean, NM
    Monia, BP
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 1997, 16 (7-9): : 917 - 926
  • [6] Targeting protein kinase C-alpha (PKC-α) in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen
    Lahn, M
    Sundell, K
    Moore, S
    THERAPEUTIC OLIGONUCLEOTIDES: ANTISENSE, RNAI, TRIPLE-HELIX, GENE REPAIR, ENHANCER DECOYS, CPG AND DNA CHIPS, 2003, 1002 : 263 - 270
  • [7] First- and second-generation antisense inhibitors targeted to human c-raf kinase: In vitro and in vivo studies
    Monia, BP
    ANTI-CANCER DRUG DESIGN, 1997, 12 (05): : 327 - 339
  • [8] A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer
    Cunningham, CC
    Holmlund, JT
    Schiller, JH
    Geary, RS
    Kwoh, TJ
    Dorr, A
    Nemunaitis, J
    CLINICAL CANCER RESEARCH, 2000, 6 (05) : 1626 - 1631
  • [9] Phase II study of c-raf kinase antisense oligonucleotide ISIS 5132 in patients (pts) with recurrent ovarian cancer -: NCICIND.116.
    Oza, AM
    Eisenhauer, E
    Swenerton, K
    Elit, L
    Ghatage, P
    Carey, M
    Faught, W
    McIntosh, L
    Dorr, A
    Holmlund, J
    CLINICAL CANCER RESEARCH, 2000, 6 : 4572S - 4572S
  • [10] Endothelin (ET) receptor stimulation of mitogen activated protein kinase (MAPK) proceeds via protein kinase-C-alpha (PKC-alpha) activation of RAF-1.
    Barnett, RL
    Josepovitz, C
    Hakker, I
    Dickman, K
    Nord, EP
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A2008 - A2008
12